4. Rome IV: What Has Changed?

5. Rome IV IBS Subtypes

6. IBS Pathophysiology

7. Rome IV: Functional Constipation

8. Epidemiology and Burden of IBS and CIC

9. Barriers to Patient Care

11. Recurrent Abdominal Pain With Disordered Bowel Habits

12. History and Physical Examination for Lower GI Symptoms

13. Alarm Features for Organic Disorders

14. Recurrent Abdominal Pain With Disordered Bowel Habits

15. Diagnostic Testing for Suspected IBS, by Subtype

16. Blood-Based Biomarker for IBS-D: Comparisons of Anti-CdtB and Anti-Vinculin Antibodies Between IBS and IBD, Celiac and Controls

17. Increased Colonic Bile Acid Exposure in IBS 75 SeHCAT Values -- Rome II Subgroups

18. Increased Bile Acid Synthesis in IBS-D

19. Recurrent Abdominal Pain With Disordered Bowel Habits

20. Diagnosis of IBS in Primary Care Positive Strategy = Strategy of Exclusion

22. Management of Patients With IBS

23. Graded Approach to Treatment of IBS

24. Dietary and Lifestyle Considerations

25. FODMAPs: Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols

26. Fiber (Bulking) Therapy for IBS

27. Probiotics

28. Medical Therapy Considerations for IBS (Non-FDA Approved)

29. FDA-Approved Therapies for IBS

30. FDA-Approved Pharmacologic Options for CIC

31. Lubiprostone

32. Linaclotide

33. Plecanatide

34. Alosetron

35. Alosetron: FDA Indication

36. Prescribing Recommendations for Alosetron

37. Eluxadoline

38. Rifaximin

39. Conclusions and Q&A

40. Abbreviations

41. Abbreviations (cont)

42. Abbreviations (cont)